C4 Therapeutics
CCCC
106 hedge funds and large institutions have $476M invested in C4 Therapeutics in 2024 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 29 increasing their positions, 27 reducing their positions, and 25 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
78% more capital invested
Capital invested by funds: $267M → $476M (+$209M)
56% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 25
49% more call options, than puts
Call options by funds: $6.88M | Put options by funds: $4.6M
15% more funds holding
Funds holding: 92 → 106 (+14)
7% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 27
10.92% less ownership
Funds ownership: 95.79% → 84.87% (-11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$54.2M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$11.1M |
| 3 |
Two Sigma Advisers
New York
|
+$9.61M |
| 4 |
Two Sigma Investments
New York
|
+$9.08M |
| 5 |
Goldman Sachs
New York
|
+$9.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$21.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.18M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$7.57M |
| 4 |
BlackRock
New York
|
-$6.96M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$6.55M |
CCCC Hedge Fund Activity: Q1 2024 in Review
106 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q1 2024, worth a combined $476M — up 78% from $267M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new CCCC positions and 25 closed out — a net gain of 14 holders — while 29 added to existing stakes and 27 trimmed.
The largest buyer was State Street, adding an estimated $54.2M. The largest seller was Wasatch Advisors, cutting an estimated $21.8M.
- 106 institutional investors held C4 Therapeutics (CCCC) as of Q1 2024, up from 92 in Q4 2023.
- Funds reported $476M of C4 Therapeutics stock for Q1 2024, up 78% quarter-over-quarter.
- 39 funds opened new C4 Therapeutics positions in Q1 2024 and 25 closed out, a net change of +14 holders.
- The largest C4 Therapeutics buyer in Q1 2024 was State Street, an estimated $54.2M added.
- The largest C4 Therapeutics seller in Q1 2024 was Wasatch Advisors, an estimated $21.8M sold.
Based on aggregated 13F filings for Q1 2024.